BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05281523 (Depemokimab in Chronic Rhinosinusitis With Nasal Polyps): BVCT ex-ante prediction vs. reported outcome

On 13 Aug 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 14 Oct 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT05281523
Acronym
ANCHOR-2
Drug Name
Depemokimab (GSK3511294)
Drug MoA
ultra-long-acting anti-IL5 mAb inhibitor
Drug Modality
monoclonal antibody
Drug Class
Best-In-Class
Therapeutic Area
Respiratory Tract Diseases
Indication
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Human Patients
264
Sponsor
GSK
Phase
Phase 3

Prediction of , index 1748

Prospective Prediction
Prediction Index
1748
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient additive clinical benefit in NPS/SNOT22 non-superior-non-inferior to tezepelumab)
Technical Prediction
SUCCESS (statistically significant additive clinical benefit in NPS/SNOT22 against placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
62 days in advance
Readout Data Interpretation
Depemokimab achieved the efficacy primary endpoint of total endoscopic nasal polyp score at week 52 and mean nasal obstruction score by week 52
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis)
Phase
Phase 3
Status
Completed
Enrollment
264
Lead sponsor
GlaxoSmithKline
Conditions
Nasal Polyps
Interventions
BIOLOGICAL: Depemokimab (GSK3511294); DRUG: Placebo
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2022-04-18
Primary completion
2024-07-12
Completion
2024-08-06
Results first posted
2025-09-09
Primary outcomes
  • Change From Baseline in Total Endoscopic Nasal Polyps (NP) Score at Week 52 (Centrally Read) (Baseline (Day 1) and at Week 52)
  • Change From Baseline in Mean Nasal Obstruction Score Using Verbal Response Scale From Weeks 49 Through to Week 52 (Baseline (Day 1) and from Week 49 to Week 52)

NCT05281523 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials